Trial Profile
An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2022
Price :
$35
*
At a glance
- Drugs Timrepigine emparvovec (Primary)
- Indications Choroideraemia
- Focus Therapeutic Use
- Acronyms REGENERATE; REGENERATE
- 07 Jul 2021 Status changed from active, no longer recruiting to completed.
- 28 Jun 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2021.
- 28 Jun 2019 Status changed from recruiting to active, no longer recruiting.